{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017313","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.654573+00:00","generated_at":"2026-06-09T00:51:47.014851+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virios provides pipeline update: IMC-1 Phase 3 partnership discussions, IMC-2 FDA briefing for Long-COVID","bullets":["FDA guidance received for IMC-1 Phase 3 fibromyalgia trial; multiple life science companies reviewing Phase 2 data for partnership.","Briefing materials submitted to FDA for IMC-2 Investigational New Drug application to treat Long-COVID (no approved LC treatments yet).","Filed provisional method-of-use patents for IMC-2 in Long-COVID and Alzheimer's disease, covering through at least 2043.","Cash runway expected to support operations into Q3 2024 due to expense management."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017313","json":"https://secwatch.observer/filing/0001558370-23-017313.json","markdown":"https://secwatch.observer/filing/0001558370-23-017313.md","text":"https://secwatch.observer/filing/0001558370-23-017313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/0001558370-23-017313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023017313/tmb-20231102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:51:47.014851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}